245 related articles for article (PubMed ID: 23472710)
21. The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project.
McIntyre RS; Soczynska JK; Cha DS; Woldeyohannes HO; Dale RS; Alsuwaidan MT; Gallaugher LA; Mansur RB; Muzina DJ; Carvalho A; Kennedy SH
J Affect Disord; 2015 Feb; 172():259-64. PubMed ID: 25451425
[TBL] [Abstract][Full Text] [Related]
22. Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study.
Akkouh IA; Skrede S; Holmgren A; Ersland KM; Hansson L; Bahrami S; Andreassen OA; Steen VM; Djurovic S; Hughes T
Neuropsychopharmacology; 2020 May; 45(6):947-955. PubMed ID: 31652432
[TBL] [Abstract][Full Text] [Related]
23. Altered glucocorticoid receptor signaling cascade in lymphocytes of bipolar disorder patients.
Spiliotaki M; Salpeas V; Malitas P; Alevizos V; Moutsatsou P
Psychoneuroendocrinology; 2006 Jul; 31(6):748-60. PubMed ID: 16621324
[TBL] [Abstract][Full Text] [Related]
24. Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder.
Machado-Vieira R; Zanetti MV; Teixeira AL; Uno M; Valiengo LL; Soeiro-de-Souza MG; Oba-Shinjo SM; de Sousa RT; Zarate CA; Gattaz WF; Marie SK
Eur Neuropsychopharmacol; 2015 Apr; 25(4):468-73. PubMed ID: 25726893
[TBL] [Abstract][Full Text] [Related]
25. Neurochemical underpinnings in bipolar disorder and epilepsy.
Amann B; Grunze H
Epilepsia; 2005; 46 Suppl 4():26-30. PubMed ID: 15938708
[TBL] [Abstract][Full Text] [Related]
26. Signaling networks in the pathophysiology and treatment of mood disorders.
Gould TD; Manji HK
J Psychosom Res; 2002 Aug; 53(2):687-97. PubMed ID: 12169343
[TBL] [Abstract][Full Text] [Related]
27. Endogenous Cardiac Steroids in Bipolar Disorder: State of the Art.
El-Mallakh RS; Sampath VP; Horesh N; Lichtstein D
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163766
[TBL] [Abstract][Full Text] [Related]
28. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression.
Bezchlibnyk Y; Young LT
Can J Psychiatry; 2002 Mar; 47(2):135-48. PubMed ID: 11926075
[TBL] [Abstract][Full Text] [Related]
29. Potential mechanisms of action of lithium in bipolar disorder. Current understanding.
Malhi GS; Tanious M; Das P; Coulston CM; Berk M
CNS Drugs; 2013 Feb; 27(2):135-53. PubMed ID: 23371914
[TBL] [Abstract][Full Text] [Related]
30. [Physiopathology of bipolar disorders: what have changed in the last 10 years?].
Kapczinski F; Frey BN; Zannatto V
Braz J Psychiatry; 2004 Oct; 26 Suppl 3():17-21. PubMed ID: 15597134
[TBL] [Abstract][Full Text] [Related]
31. Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder: A 3-T 1H-MRS Study.
Machado-Vieira R; Zanetti MV; Otaduy MC; De Sousa RT; Soeiro-de-Souza MG; Costa AC; Carvalho AF; Leite CC; Busatto GF; Zarate CA; Gattaz WF
J Clin Psychopharmacol; 2017 Feb; 37(1):40-45. PubMed ID: 27902528
[TBL] [Abstract][Full Text] [Related]
32. Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium.
Stewart RJ; Chen B; Dowlatshahi D; MacQueen GM; Young LT
Brain Res Bull; 2001 Jul; 55(5):625-9. PubMed ID: 11576759
[TBL] [Abstract][Full Text] [Related]
33. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder.
Beasley C; Cotter D; Everall I
Schizophr Res; 2002 Nov; 58(1):63-7. PubMed ID: 12363391
[TBL] [Abstract][Full Text] [Related]
34. Antiapoptotic action of lithium and valproate.
Bielecka AM; Obuchowicz E
Pharmacol Rep; 2008; 60(6):771-82. PubMed ID: 19211968
[TBL] [Abstract][Full Text] [Related]
35. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness.
Manji HK; Moore GJ; Chen G
J Clin Psychiatry; 2000; 61 Suppl 9():82-96. PubMed ID: 10826666
[TBL] [Abstract][Full Text] [Related]
36. The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment.
de Bartolomeis A; Buonaguro EF; Iasevoli F; Tomasetti C
J Psychopharmacol; 2014 Jun; 28(6):505-26. PubMed ID: 24554693
[TBL] [Abstract][Full Text] [Related]
37. Finding the intracellular signaling pathways affected by mood disorder treatments.
Coyle JT; Duman RS
Neuron; 2003 Apr; 38(2):157-60. PubMed ID: 12718851
[TBL] [Abstract][Full Text] [Related]
38. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
39. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder.
Shaltiel G; Chen G; Manji HK
Curr Opin Pharmacol; 2007 Feb; 7(1):22-6. PubMed ID: 17055337
[TBL] [Abstract][Full Text] [Related]
40. Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes.
Stoll AL; Severus WE
Harv Rev Psychiatry; 1996; 4(2):77-89. PubMed ID: 9384977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
